ICCC Q1 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-42.6% YoY

Gross Profit

$300,7758.7% margin

Operating Income

-$2M-65.5% margin

Net Income

-$2M-67.2% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-11.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$96,116

Balance Sheet

Total Assets

$43M

Total Liabilities

$15M

Stockholders' Equity

$28M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$6M	-42.6%
Gross Profit	$300,775	$3M	-90.3%
Operating Income	-$2M	$570,609	-495.4%
Net Income	-$2M	$513,287	-551.0%